SELLAS Life Sciences Group Future Growth
Future criteria checks 0/6
SELLAS Life Sciences Group is forecast to grow earnings and revenue by 40.2% and 72.8% per annum respectively while EPS is expected to grow by 44.9% per annum.
Key information
40.2%
Earnings growth rate
44.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 72.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -37 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -34 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -31 | N/A | N/A | 2 |
| 9/30/2024 | N/A | -32 | -33 | -33 | N/A |
| 6/30/2024 | N/A | -34 | -35 | -32 | N/A |
| 3/31/2024 | N/A | -36 | -36 | -30 | N/A |
| 12/31/2023 | N/A | -37 | -37 | -31 | N/A |
| 9/30/2023 | N/A | -38 | -37 | -32 | N/A |
| 6/30/2023 | N/A | -36 | -33 | -31 | N/A |
| 3/31/2023 | N/A | -36 | -33 | -29 | N/A |
| 12/31/2022 | 1 | -41 | -28 | -24 | N/A |
| 9/30/2022 | 1 | -39 | -28 | -24 | N/A |
| 6/30/2022 | 1 | -39 | -28 | -24 | N/A |
| 3/31/2022 | 3 | -35 | -23 | -23 | N/A |
| 12/31/2021 | 8 | -21 | -26 | -26 | N/A |
| 9/30/2021 | 10 | -18 | -18 | -18 | N/A |
| 6/30/2021 | 10 | -15 | -15 | -15 | N/A |
| 3/31/2021 | 8 | -15 | -14 | -14 | N/A |
| 12/31/2020 | 2 | -17 | -10 | -10 | N/A |
| 9/30/2020 | N/A | -21 | -18 | -18 | N/A |
| 6/30/2020 | N/A | -28 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -27 | -19 | -19 | N/A |
| 12/31/2019 | N/A | -28 | -18 | -18 | N/A |
| 9/30/2019 | N/A | -34 | -18 | -18 | N/A |
| 6/30/2019 | N/A | -32 | -28 | -28 | N/A |
| 3/31/2019 | N/A | -36 | -30 | -30 | N/A |
| 12/31/2018 | N/A | -41 | -30 | -30 | N/A |
| 9/30/2018 | N/A | -37 | -28 | -28 | N/A |
| 6/30/2018 | N/A | -32 | N/A | -16 | N/A |
| 3/31/2018 | N/A | -30 | N/A | -13 | N/A |
| 12/31/2017 | N/A | -24 | N/A | -11 | N/A |
| 9/30/2017 | N/A | -21 | N/A | -14 | N/A |
| 6/30/2017 | N/A | -23 | N/A | -16 | N/A |
| 3/31/2017 | N/A | -20 | N/A | -14 | N/A |
| 12/31/2016 | N/A | -18 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXK3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXK3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXK3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXK3 is forecast to have no revenue next year.
High Growth Revenue: RXK3 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RXK3's Return on Equity is forecast to be high in 3 years time